SSRIs associated with decreased risk of hepatocellular carcinoma: A population-based case-control study.

<bold>Background: </bold>Hepatocellular carcinoma (HCC) is the second leading cancer-related cause of mortality worldwide. Antidepressants, especially selective serotonin reuptake inhibitors (SSRIs), are commonly used worldwide. Available evidence investigating the association between SSRIs use and HCC risk is limited.<bold>Objective: </bold>The present study aimed to investigate if the effect of all kinds of SSRIs on HCC was the same or not using population-based study.<bold>Methods: </bold>The nationwide population-based study herein using Taiwan's National Health Insurance Research Database included a total of 59 859 cases with HCC and 285 124 matched controls. Conditional logistic regression analyses were adjusted for confounding variables.<bold>Results: </bold>All common kinds of SSRIs including fluoxetine, sertraline, paroxetine, citalopram, escitalopram, and fluvoxamine were associated with lower HCC risk, and the findings were dose-dependent (eg, fluoxetine: 1-28 DDD [defined daily dose]: adjusted odds ratio [aOR]: 0.81, 95% confidence interval [CI], 0.73-0.89; 29-365 DDD: aOR: 0.71, 95% CI, 0.64-0.79; and ≥366 DDD: aOR: 0.55, 95% CI, 0.45-0.67) (P for trend < .001).<bold>Conclusions: </bold>All kinds of SSRIs were associated with decreased risk of HCC. [ABSTRACT FROM AUTHOR]